Injection Therapy for Erectile Dysfunction
- 4 April 1996
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 334 (14) , 913-914
- https://doi.org/10.1056/nejm199604043341409
Abstract
In this issue of the Journal, Linet and Ogrinc report that intracavernous-injection therapy with alprostadil (a synthetic prostaglandin E1) can produce good results in men with erectile dysfunction (impotence).1 It should be emphasized that the proper treatment of such men requires individualized evaluation and depends on the cause of their erectile dysfunction. The first step in management of erectile dysfunction is a comprehensive investigation that begins with a thorough medical history and physical examination. The causes are diverse and may be hormonal, psychological, vasculogenic, or neurogenic. Medications, especially antihypertensive and psychotropic drugs, can also cause impotence. Commonly, serum . . .Keywords
This publication has 9 references indexed in Scilit:
- Efficacy and Safety of Intracavernosal Alprostadil in Men with Erectile DysfunctionNew England Journal of Medicine, 1996
- Topical Prostaglandin-E1 for the Treatment of Erectile DysfunctionJournal of Urology, 1995
- The latorre patent issue: Extortion or entrepreneurshipUrology, 1995
- Tunica Vaginalis Blanket Wrap to Prevent Urethrocutaneous Fistula: An 8-Year ExperienceJournal of Urology, 1995
- Experience with Triple-Drug Therapy in a Pharmacological Erection ProgramJournal of Urology, 1993
- Pharmacological Erection Program Using Prostaglandin E1Journal of Urology, 1991
- Intracavernous Injection Therapy: Analysis of Results and ComplicationsJournal of Urology, 1990
- Cavernosal Alpha-Blockade: A New Technique for Investigating and Treating Erectile ImpotenceThe British Journal of Psychiatry, 1983
- INTRACAVERNOUS INJECTION OF PAPAVERINE FOR ERECTILE FAILUREThe Lancet, 1982